AstraZeneca Sues Ivax, Teva Over Nexium Patent

Law360, New York (October 13, 2008, 12:00 AM EDT) -- AstraZeneca AB has asserted its latest patent for blockbuster heartburn treatment Nexium against Teva Pharmaceutical Industries Ltd.

The complaint, filed Thursday in the U.S. District Court for the District of New Jersey, alleges that Teva and subsidiary Ivax Corp. infringed AstraZeneca's Aug. 12 patent for a delayed-release version of Nexium's active ingredient with an abbreviated new drug application.

The generics manufacturer has sought approval from the U.S. Food and Drug Administration to market 20- and 40-milligram esomeprazole magnesium delayed-release capsules before the patent expires in 2018,...
To view the full article, register now.